A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer(†)

BACKGROUND: We evaluated the efficacy and toxicity of adding oral leucovorin (LV) to S-1 when compared with S-1 monotherapy in patients with gemcitabine-refractory pancreatic cancer (PC). PATIENTS AND METHODS: Gemcitabine-refractory PC patients were randomly assigned in a 1:1 ratio to receive S-1 at...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Ueno, M., Okusaka, T., Omuro, Y., Isayama, H., Fukutomi, A., Ikeda, M., Mizuno, N., Fukuzawa, K., Furukawa, M., Iguchi, H., Sugimori, K., Furuse, J., Shimada, K., Ioka, T., Nakamori, S., Baba, H., Komatsu, Y., Takeuchi, M., Hyodo, I., Boku, N.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4769993/
https://ncbi.nlm.nih.gov/pubmed/26681680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv603
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars